Company

TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with a commercial product and a strong clinical stage pipeline of adult stem cell programs. The company’s lead product, ChondroCelect®, for cartilage repair in the knee, is the first approved cell-based product in Europe, and is currently being sold across Europe. TiGenix’s adipose derived allogeneic stem cell platform has been extensively validated. The company is in Phase III to treat complex perianal fistulas in patients with Crohn’s disease, has successfully concluded a Phase IIa trial in rheumatoid arthritis, as well as a Phase I trial to investigate intra-lymphatic administration in autoimmune disorders. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). 

Read more...

Products

Read more...

Latest News

17 April 2014 - VFB - E-news - Interview with Eduardo Bravo (EN)

4 April 2014 - Convening Notice to the Extraordinary Shareholders' Meeting of 22 April 2014 (EN - NL)

3 April 2014 - TiGenix licenses exclusive marketing and distribution rights for ChondroCelect to Sobi (EN - NL - FR)

21 March 2014 - Convening Notice to the Annual Shareholders' Meeting - 22 April 2014 (EN - NL)

11 March 2014 - TiGenix Full Year 2013 Results (EN - NL - FR) - MP3 - Financial Statement EN - FY 2013 Results Presentation (EN)

Read more...

Events

9th edition European Smallcap Event,
April 7-8, Paris, France
Request meeting

9th Annual World Stem Cell & Regenerative Medicine Congress
May 20-22, London, UK
Request meeting

BioEquity Europe 2014
May 21-22, Amsterdam, the Netherlands
Request meeting

Bio International Convention,
June 23-26, San Diego, U.S.
Request meeting

Read more...